哈药股份：关于所属企业药品通过仿制药一致性评价的公告

Group 1 - The core point of the article is that Harbin Pharmaceutical Group has received approval from the National Medical Products Administration for the supplementary application of Lercanidipine tablets, which have passed the consistency evaluation of quality and efficacy for generic drugs [2] Group 2 - Harbin Pharmaceutical Group's subsidiary, Harbin Pharmaceutical Group Sanjing Ming Shui Pharmaceutical Co., Ltd., is the entity that received the approval [2] - The approval signifies a significant milestone for the company in the generic drug market, enhancing its product portfolio [2] - The successful evaluation indicates that the product meets the required standards for quality and therapeutic effectiveness, which may lead to increased market competitiveness [2]